Aspira Women’s Health (NASDAQ:AWH) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report sent to investors on Saturday. The brokerage issued a hold rating on the stock.

Separately, Cantor Fitzgerald restated a neutral rating and issued a $3.30 target price on shares of Aspira Women’s Health in a research note on Wednesday, April 10th.

Aspira Women’s Health Trading Down 3.3 %

Shares of NASDAQ:AWH opened at $3.22 on Friday. The stock has a market cap of $39.73 million, a PE ratio of -0.27 and a beta of 1.61. The stock’s fifty day simple moving average is $3.55 and its two-hundred day simple moving average is $3.97. Aspira Women’s Health has a 1-year low of $2.31 and a 1-year high of $6.75.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.09. Aspira Women’s Health had a negative net margin of 176.74% and a negative return on equity of 1,099.32%. The company had revenue of $2.13 million for the quarter, compared to analyst estimates of $2.70 million. On average, sell-side analysts forecast that Aspira Women’s Health will post -1.24 earnings per share for the current fiscal year.

Institutional Trading of Aspira Women’s Health

A number of large investors have recently added to or reduced their stakes in the stock. Northeast Financial Consultants Inc purchased a new stake in Aspira Women’s Health in the third quarter worth $126,000. Quantum Private Wealth LLC grew its stake in shares of Aspira Women’s Health by 76.8% during the 4th quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock worth $205,000 after acquiring an additional 21,788 shares during the period. Perkins Capital Management Inc. bought a new position in shares of Aspira Women’s Health during the 3rd quarter worth $268,000. Finally, B. Riley Wealth Advisors Inc. increased its holdings in Aspira Women’s Health by 39.0% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 125,374 shares of the company’s stock worth $672,000 after acquiring an additional 35,177 shares during the last quarter. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.